Pharmaceuticals News and Research

RSS

Iowa State acquires new state-of-the-art "T-ray" tool

A new, $500,000 instrument recently went about its work emitting and reading high-speed pulses of silent and invisible terahertz rays.

27 Oct 2009

Shire reports results of Lialda and 5-ASA persistency analyses

Shire plc, the global specialty biopharmaceutical company, presented the results of three 5-aminosalicylic acid (5-ASA) persistency analyses at ACG 2009 Annual Scientific Meeting, evaluating persistency of Lialda® (mesalamine), Asacol® (mesalamine), Pentasa® (mesalamine) (250mg and 500mg), balsalazide [combined results from generic balsalazide disodium and Colazal® (balsalazide disodium)], and Dipentum® (olsalazine sodium) (500mg).

27 Oct 2009

TNF-alpha inhibitors and interleukin inhibitors to drive psoriasis drug market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of marketed and emerging TNF-alpha inhibitors and interleukin inhibitors will drive the psoriasis drug market to increase from $3 billion in 2008 to $5.2 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

27 Oct 2009

Impax Pharmaceuticals begins Phase III trial of IPX066 drug in PD patients

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ:IPXL), today announced that it has initiated a multinational Phase III trial of its late-stage drug candidate IPX066 in advanced Parkinson’s disease (PD) patients.

27 Oct 2009

Third quarter 2009 results announced by Genomma Lab Internacional

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), announced today its results for the quarter ended September 30, 2009.

27 Oct 2009

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

Inhibikase Therapeutics, a specialty pharmaceutical company based in Atlanta, Georgia, will discuss simultaneous antiviral and antibacterial activity from small molecule agents at the 2009 BIOCOM Investor Conference. Employing a host-factor targeted approach, Inhibikase will illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases in humans.

27 Oct 2009

New data demonstrates CREON Delayed-Release Capsules improve fat absorption in adults with EPI

Solvay Pharmaceuticals, Inc. announced that new data demonstrate that CREON®( )(pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in adults with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery.

27 Oct 2009

Clinical trial helps improve prognosis and changes the standard of care for patients with colorectal cancer

In a review article published this month in The Oncologist, UNC's Dr. Richard M. Goldberg and a team of colleagues catalogue how the data collected in a single large comparative clinical trial testing combination chemotherapy for metastatic colorectal cancer has been used not only to benefit the patients that enrolled but also patients who subsequently developed the disease.

27 Oct 2009

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

BioMarin Pharmaceutical Inc. announced today that it has acquired Huxley Pharmaceuticals, Inc. (Huxley), which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).

27 Oct 2009

Opinions: Africa Food Aid; International Violence Against Women Act; brain drain

While the drought and starvation in the Horn of Africa are "ghastly to be sure," when "you see children on TV with distended bellies keening over their dying parents ... do them a favour. Sit on your hands," Sam Kiley, a former Africa bureau chief with the London Times, writes in a newspaper opinion piece.

27 Oct 2009

Innovative approach to build a new drug to treat a number of CNS diseases

Working like an architect, Prof. Hagit Eldar-Finkelman of Tel Aviv University's Sackler School of Medicine is "building" a new drug, L803-MTS, to treat a number of central nervous system (CNS) diseases like Alzheimer's. In pre-clinical studies, it also shows promise against Parkinson's, Huntington's and diabetes.

27 Oct 2009

Analysis from Phase 3 trials of HZT-501 presented at 74th ACG meeting

Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today presented an analysis from two pivotal Phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine.

26 Oct 2009

Wound Management Technologies signs distribution agreement with Biocure S.r.l. of Milan

Wound Management Technologies, Inc., through its subsidiary, Wound Care Innovations, announced today that it has reached an agreement with Biocure S.r.l. of Milan, Italy for the distribution of WNDM's patented molecular form of activated collagen, CellerateRx®.

26 Oct 2009

Cephalon, BDC sign option agreement

Cephalon, Inc. and BioAssets Development Corporation (BDC), a privately held biopharmaceutical company, today announced that the companies have signed an agreement that will provide Cephalon with an option to acquire BDC.

26 Oct 2009

StayinFront signs agreements with two leading biopharma companies to deploy StayinFront EdgeRx

StayinFront, Inc., a leading global provider of CRM and decision support solutions, announced today that they have reached agreements with two leading biopharma companies to deploy StayinFront EdgeRx. Announced only recently, StayinFront EdgeRx is the new On Demand CRM and analytics solution that offers superior functionality and performance from a company that has been delivering cutting edge CRM solutions to the industry for 20 years.

26 Oct 2009

Rexahn Pharmaceuticals completes Registered Direct Offering of common stock and warrants

Rexahn Pharmaceuticals, Inc. announced today that it has completed its previously announced Registered Direct Offering of common stock and warrants. Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NasdaqGM: RODM), acted as the exclusive placement agent for this transaction.

26 Oct 2009

Overview of Compugen’s DAC Blockers Platform presented at Fifth Peptide Engineering Meeting

Speaking today in Barcelona at the Fifth Peptide Engineering Meeting, Compugen Ltd. project manager Dr. Yossef Kliger provided an overview of Compugen’s DAC Blockers Platform and reviewed disease model data for selected product candidates.

26 Oct 2009

Ceragenix Pharmaceuticals updates its cooperative research and development with MAST BioSurgery

Ceragenix Pharmaceuticals, Inc. ("Ceragenix" or the “Company”), a medical device company focused on infectious disease and dermatology, today provided an update to a previously announced exclusive cooperative research and development (the "Agreement”) with MAST BioSurgery Inc. (“MAST”) for the development of one or more new surgical products incorporating Ceragenix’s CeraShield™ antimicrobial technology.

26 Oct 2009

Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals

Napo Pharmaceuticals, Inc. has in-licensed from the University of California Regents additional small-molecule cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor technology including gastrointestinal (GI) and polycystic kidney disease (PKD) indications.

26 Oct 2009

Rega Institute and CD3 to receive funds for new medication research for dengue treatment

The Laboratory for Virology and Experimental Chemotherapy (Rega Institute) and the "Centre for Drug Design and Discovery" (CD3) at K.U.Leuven will receive a total of 2.8 million euro from the British Wellcome Trust. - They will apply these funds to the search for possible new medication for the treatment of infections related to the 'dengue fever virus'.

26 Oct 2009

Pharmaceuticals News and Research

Iowa State acquires new state-of-the-art "T-ray" tool

Shire reports results of Lialda and 5-ASA persistency analyses

TNF-alpha inhibitors and interleukin inhibitors to drive psoriasis drug market

Impax Pharmaceuticals begins Phase III trial of IPX066 drug in PD patients

Third quarter 2009 results announced by Genomma Lab Internacional

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

New data demonstrates CREON Delayed-Release Capsules improve fat absorption in adults with EPI

Clinical trial helps improve prognosis and changes the standard of care for patients with colorectal cancer

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

Opinions: Africa Food Aid; International Violence Against Women Act; brain drain

Innovative approach to build a new drug to treat a number of CNS diseases

Analysis from Phase 3 trials of HZT-501 presented at 74th ACG meeting

Wound Management Technologies signs distribution agreement with Biocure S.r.l. of Milan

Cephalon, BDC sign option agreement

StayinFront signs agreements with two leading biopharma companies to deploy StayinFront EdgeRx

Rexahn Pharmaceuticals completes Registered Direct Offering of common stock and warrants

Overview of Compugen’s DAC Blockers Platform presented at Fifth Peptide Engineering Meeting

Ceragenix Pharmaceuticals updates its cooperative research and development with MAST BioSurgery

Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals

Rega Institute and CD3 to receive funds for new medication research for dengue treatment

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring